高级检索

    超声造影联合血清lncRNA PCAT6检测对乳腺癌的诊断价值

    Value of contrast-enhanced ultrasound combined with serum lncRNA PCAT6 detection in the diagnosis of breast cancer

      摘要
    • 摘要:
      目的 探讨超声造影联合血清长链非编码RNA(lncRNA)前列腺相关转录本6(PCAT6)检测对乳腺癌的诊断价值。
      方法 选取72例乳腺癌病人作为乳腺癌组，68例乳腺良性疾病病人作为乳腺良性疾病组。所有受试者均进行超声造影检查及血清lncRNA PCAT6、糖类抗原153(CA153)水平检测。分析超声造影检查、血清lncRNA PCAT6、CA153诊断乳腺癌的价值。
      结果 乳腺癌组病人高增强占比、增强后病灶增大占比均明显高于乳腺良性疾病组(P < 0.01)。超声造影诊断乳腺癌的灵敏度为73.61%，特异度为89.71%，准确度为81.43%。乳腺癌组病人血清lncRNA PCAT6、CA153水平均明显高于乳腺良性疾病组(P < 0.01)。血清lncRNA PCAT6、CA153诊断乳腺癌的AUC分别为0.882、0.719，截断值分别为1.56、27.28 U/mL，灵敏度分别为76.39%、61.11%，特异度分别为88.24%、82.35%，准确度分别为82.14%、71.43%。超声造影检查联合血清lncRNA PCAT6诊断乳腺癌的灵敏度为98.61%，特异度为86.76%，准确度为92.86%。
      结论 超声造影检查联合血清lncRNA PCAT6检测诊断乳腺癌的价值较高，有望成为早期诊断乳腺癌的一种临床参考方案。

       

      Abstract:
      Objective To investigate the diagnostic value of contrast-enhanced ultrasound combined with serum long non-coding RNA(lncRNA) prostate cancer-associated transcript 6(PCAT6) detection in breast cancer.
      Methods A total of 72 patients with breast cancer were selected as breast cancer group, and 68 patients with benign breast diseases were selected as breast benign disease group.The contrast-enhanced ultrasound were performed in two groups, and the serum levels of lncRNA PCAT6 and carbohydrate antigen 153(CA153) levels were detected.The value of contrast-enhanced ultrasound and serum levels of lncRNA PCAT6 and CA153 in the diagnosis of breast cancer were analyzed.
      Results The proportions of high enhancement and lesion enlargement in breast cancer group were significanthy higher than those in benign breast disease group(P < 0.01).The sensitivity, specificity and accuracy of contrast-enhanced ultrasound in the diagnosis of breast cancer were 73.61%, 89.71% and 81.43%, respectively.The serum levels of lncRNA PCAT6 and CA153 in the breast cancer group were significantly higher than those in benign breast disease group(P < 0.01).The AUC, cut-off value, sensitivity, specificity and accuracy of serum lncRNA PCAT6 and CA153 in the diagnosis of breast cancer were (0.882 and 0.719), (1.56 and 27.28 U/mL), (76.39% and 61.11%).The sensitivity, specificity and accuracy of contrast-enhanced ultrasound combined with serum lncRNA PCAT6 in the diagnosis of breast cancer were 98.61%, 86.76% and 92.86%, respectively.
      Conclusions The contrast-enhanced ultrasound combined with serum lncRNA PCAT6 detection has high value in the diagnosis of breast cancer, and it is expected to become a clinical reference scheme for early diagnosis of breast cancer.

       

      • HTML全文
      • 参考文献(23)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回